-
Journal of the European Academy of... Oct 2021
Topics: Drug Eruptions; Exanthema; Humans; Pharmaceutical Preparations; Vaccines
PubMed: 34138472
DOI: 10.1111/jdv.17454 -
CMAJ : Canadian Medical Association... Oct 2013
Topics: Adult; Animals; Drug Eruptions; Female; Hand Dermatoses; Humans; Rat-Bite Fever; Rats; Streptobacillus
PubMed: 23529964
DOI: 10.1503/cmaj.121704 -
Acta Dermato-venereologica Apr 2024
Topics: Humans; Drug Eruptions; Antibodies, Monoclonal, Humanized
PubMed: 38643361
DOI: 10.2340/actadv.v104.37804 -
Acta Dermato-venereologica Jun 2019
Topics: Administration, Oral; Carbocysteine; Child, Preschool; Drug Eruptions; Follow-Up Studies; Humans; Male; Respiratory Tract Infections; Risk Assessment; Severity of Illness Index; Skin Tests
PubMed: 30938829
DOI: 10.2340/00015555-3193 -
Revue Medicale de Liege Oct 2017Some drug eruptions are frequent and follow an indolent course, while others prove to be life-threatening. By contrast, SCAR syndromes are serious skin drug reactions...
Some drug eruptions are frequent and follow an indolent course, while others prove to be life-threatening. By contrast, SCAR syndromes are serious skin drug reactions that are rare but their vital prognosis is affected. The three distinct entities of importance are the former Lyell's syndrome, now identified as SJS-TEN syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis), the DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), and the AGEP syndrome (acute generalized exanthematous pustulosis).
Topics: Acute Generalized Exanthematous Pustulosis; Drug Hypersensitivity Syndrome; Humans; Stevens-Johnson Syndrome
PubMed: 29058836
DOI: No ID Found -
Allergology International : Official... Jul 2016
Review
Topics: Aged; Antiviral Agents; Biopsy; Drug Eruptions; Guanine; Hepatitis B; Humans; Male; Skin
PubMed: 26818490
DOI: 10.1016/j.alit.2015.12.008 -
La Revue de Medecine Interne Apr 2015Cutaneous adverse drug reactions (CADR) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality....
Cutaneous adverse drug reactions (CADR) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality. Exanthematous eruptions, urticaria and vasculitis are the most common forms of CADR. Fixed eruption is uncommon in western countries. Serious reactions (fatal outcome, sequelae) represent 2% of CADR: bullous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), DRESS (drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity syndrome) and acute generalized exanthematous pustulosis (AGEP). These forms must be quickly diagnosed to guide their management. The main risk factors are immunosuppression, autoimmunity and some HLA alleles in bullous reactions and DRESS. Most systemic drugs may induce cutaneous adverse reactions, especially antibiotics, anticonvulsivants, antineoplastic drugs, non-steroidal anti-inflammatory drugs, allopurinol and contrast media. Pathogenesis includes immediate or delayed immunologic mechanism, usually not related to dose, and pharmacologic/toxic mechanism, commonly dose-dependent or time-dependent. In case of immunologic mechanism, allergologic exploration is possible to clarify drug causality, with a variable sensitivity according to the drug and to the CADR type. It includes epicutaneous patch testing, prick test and intradermal test. However, no in vivo or in vitro test can confirm the drug causality. To determine the cause of the eruption, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis is required, completed with a literature search. A reporting to pharmacovigilance network is essential in case of a serious CADR whatever the suspected drug and in any case if the involved drug is a newly marketed one or unusually related to cutaneous reactions.
Topics: Antineoplastic Agents; Drug Eruptions; Humans
PubMed: 25458866
DOI: 10.1016/j.revmed.2014.10.004 -
Indian Journal of Pharmacology 2012Fixed drug eruption (FDE) is mainly characterized by skin lesions that recur at the same anatomic sites upon repeated exposures to an offending agent. It represents the... (Review)
Review
Fixed drug eruption (FDE) is mainly characterized by skin lesions that recur at the same anatomic sites upon repeated exposures to an offending agent. It represents the most common cutaneous adverse drug reaction pattern in Indian patients. Here, we report an FDE to fluconazole.
Topics: Adult; Antifungal Agents; Drug Eruptions; Fluconazole; Humans; Male; Steroids
PubMed: 23112430
DOI: 10.4103/0253-7613.100403 -
BMC Psychiatry Mar 2021Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses. Clonazepam, a commonly used drug for the treatment of anxiety-related...
BACKGROUND
Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses. Clonazepam, a commonly used drug for the treatment of anxiety-related disorders and seizures, is known to be an unlikely cause of cutaneous adverse effects. Only one case report of LDE due to clonazepam has been reported.
CASE PRESENTATION
A 81-year-old male patient with Alzheimer's disease developed a lichenoid eruption after taking clonazepam. He developed a violaceous scaly patch on his lower extremities, from both buttocks to the feet. The cutaneous eruption resolved 2 months after cessation of clonazepam and with initiation of corticosteroid therapy.
CONCLUSION
A skin eruption that develops after clonazepam administration can be a lichenoid drug eruption, which is less likely to resolve spontaneously and requires discontinuation of clonazepam administration.
Topics: Aged, 80 and over; Clonazepam; Drug Eruptions; Humans; Lichen Planus; Lichenoid Eruptions; Male
PubMed: 33663441
DOI: 10.1186/s12888-021-03132-2 -
Allergology International : Official... Jan 2018In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these... (Clinical Trial)
Clinical Trial
BACKGROUND
In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation.
METHODS
Study participants included 76 patients who received a diagnosis of a drug eruption, one of the following: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, maculopapular exanthema, and erythema multiforme. Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) was eliminated in this study because scoring system for evaluating the severity was established. Correlation coefficients between serum TARC levels and indicators of systemic inflammation, including the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, modified systemic inflammatory response syndrome (mSIRS) score, and C-reactive protein in serum were evaluated.
RESULTS
Serum TARC levels positively correlated with the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, mSIRS score, C-reactive protein, albumin, white blood cell count, body temperature, and pulse rate. TARC levels negatively correlated with systolic blood pressure. Among these parameters, the mSIRS score showed strong correlation (correlation coefficient: 0.68).
CONCLUSIONS
Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; C-Reactive Protein; Chemokine CCL17; Child; Drug Eruptions; Female; Humans; Leukocyte Count; Male; Middle Aged; Systemic Inflammatory Response Syndrome
PubMed: 28648978
DOI: 10.1016/j.alit.2017.06.001